Laboratory markers and risk of secondary hemorrhagic complications after anticoagulation due to venous thromboembolism in the early postoperative phase after neurosurgical procedures

Deep venous thromboses (DVT) and venous thromboembolisms (VTE) are serious complications after neurosurgical procedures. Hemorrhagic complications of thera-peutic anticoagulation on the other hand are also highly dreaded due to the high risk of permanent neurological deficit. Clear guidelines concerning dosage and duration of anticoagulation still do not exist for neurosurgical practice. Over a 10-year episode, patients with postoperative DVT or VTE were retrospectively identified and demographic risk factors as well as routine laboratory coagulation parameters were assessed. The goal was to determine patients at risk for a severe course of thrombosis and complications due to anticoagulation. In total, 173 patients with DVT or VTE were identified. Clinical effect of thrombosis was severe in 32.4% and fatal in 5.8% of all patients. Spinal surgery was associated with a higher risk of major or fatal outcome of thrombosis as compared to cranial procedures (fatal: 12.1 vs. 4.3%, p = 0.035). Elevated partial thromboplastin time, low platelet levels and low quick on diagnosis of thrombosis were associated with a fatal clinical course (p = 0.02, 0.04 and 0.02 respectively). Severe hemorrhagic complications on the other hand occurred in 6.6%, 0.6% were fatal. D-dimer did not predict the course of DVT/VTE but higher levels of D-dimer on day 3 after diagnosis of DVT/VTE were associated with a higher risk of severe bleeding complications (cutoff 4.95 µg/mL). Partial thromboplastin time after initiation of anticoagulation was not associated with hemorrhagic complications and might thus be not helpful to determine the risk of bleeding complications during the early postoperative phase. D-dimer might be of additional use to detect early bleeding complications.

Deep venous thrombosis; Pulmonary embolism; Neurosurgery; D-dimer; Laboratory marker

[1] Aishima K, Yoshimoto Y. Screening strategy using sequential serum D-dimer assay for the detection and prevention of venous thromboembolism after elective brain tumor surgery. British Journal of Neurosurgery. 2013; 27: 348–354.

[2] Bowcock E, Morris I, Lane S. Disseminating clot burden post-craniotomy: the difficult balancing act of clot versus haemorrhage post-neurosurgery. Journal of Neuroanaesthesiology and Critical Care. 2016; 3: 252–258.

[3] Glober N, Tainter CR, Brennan J, Darocki M, Klingfus M, Choi M, et al. Use of the d-dimer for detecting pulmonary embolism in the emergency department. The Journal of Emergency Medicine. 2018; 54: 585–592.

[4] Hamidi S, Riazi M. Cutoff values of plasma d-dimer level in patients with diagnosis of the venous thromboembolism after elective spinal surgery. Asian Spine Journal. 2015; 9: 232–238.

[5] Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Archives of Internal Medicine. 2000; 160: 2327–2332.

[6] Schreiber DH. The role of D-dimer in the diagnosis of venous thromboembolism. Laboratory Medicine. 2002; 33: 136–141.

[7] Kévorkian JP, Halimi C, Segrestaa JM, Drouet L, Soria C. Monitoring of patients with deep-vein thrombosis during and after anticoagulation with D- dimer. The Lancet. 1998; 351: 571–572.

[8] Levi M. Disseminated intravascular coagulation or extended intravascular coagulation in massive pulmonary embolism. Journal of Thrombosis and Haemostasis. 2010; 8: 1475–1476.

[9] Prell J, Rachinger J, Smaczny R, Taute BM, Rampp S, Illert J, et al. D-dimer plasma level: a reliable marker for venous thromboembolism after elective craniotomy. Journal of Neurosurgery. 2013; 119: 1340–1346.

[10] Smith TR, Nanney AD 3rd, Lall RR, Graham RB, McClendon Jr, Lall RR, et al. Development of venous thromboembolism (VTE) in patients undergoing surgery for brain tumors: results from a single center over a 10 year period. Journal of Clinical Neuroscience. 2015; 22: 519–525.

[11] Soomro AY, Guerchicoff A, Nichols DJ, Suleman J, Dangas GD. The current role and future prospects of D-dimer biomarker. European Heart Journal-Cardiovascular Pharmacotherapy. 2016; 2: 175–184.

[12] Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Journal of Thrombosis and Thrombolysis. 2016; 41: 32–67.

[13] Tamizifar B, Oghab P, Esfahani MA. The prediction role of D-dimer in recurrence of venous thromboembolism 1-year after anticoagulation discontinuing following idiopathic deep vein thrombosis. Journal of Research in Medical Sciences. 2014; 19: 586–591.

[14] Venugopal A. Disseminated intravascular coagulation. Indian Journal of Anaesthesia. 2014; 58: 603–608.

[15] Yin X, Liu P, Liu BY, Liu YY, Fan WL, Zhao JH. Preventive effects of low molecular weight heparin on formation of deep vein thrombosis by reducing d dimer values in patients undergoing spinal surgery. European Review for Medical and Pharmacological Sciences. 2018; 22: 229–237.

[16] Yoshiiwa T, Miyazaki M, Takita C, Itonaga I, Tsumura H. Analysis of measured D-dimer levels for detection of deep venous thrombosis and pulmonary embolism after spinal surgery. Journal of Spinal Disorders & Techniques. 2011; 24: E35–E39.

[17] Zidane M, Schram MT, Planken EW, Molendijk WH, Rosendaal FR, van der Meer FJ, et al. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice. Archives of Internal Medicine. 2000; 160: 2369–2373.